Top of this page
Skip navigation, go straight to the content
UCB is a global biopharmaceutical company focused on creating value for people living with severe diseases in immunology and neurology.
We work with stakeholders to address the unmet needs of patients and caregivers, helping them to achieve their goals and to live the lives they want. UCB is on a journey to become the patient-preferred biopharma leader by delivering medicines and solutions that improve lives. Our commitment to value is a promise to bring together the talent, expertise, tools and scientific know-how required to serve patients in need.
UCBCares: Providing Dedicated Patient Support
Clinical studies at UCB: How are medicines made and tested?
Twitter Feed
-
We recognize that people with #rarediseases can feel forgotten or unheard at times, and we want them to know we see them and are here for them. Our Global Mission Lead, Chris Clark, shares his perspective on how UCB is making a difference in their lives h
— UCB News (@ucb_news) 25.02.2020 -
While immune thrombocytopenia (ITP) affects less than 1% of the world's population, those living with ITP can experience debilitating symptoms that impact their daily lives. #RallyForRare https://t.co/PdPUNMELaD https://t.co/BqL7nJ0eV9
— UCB News (@ucb_news) 24.02.2020 -
In the lead up to #RareDiseaseDay we’ll be sharing insights on the unmet needs of people living with #progressivesupranuclearpalsy (PSP). Charl van Zyl, Head of Neurology Solutions, explains the focus of UCB’s work in PSP. Find out more here: https://t.co
— UCB News (@ucb_news) 24.02.2020
Instagram Feed
At UCB, we take our responsibility
to the planet very seriously.
UCB Ventures, our strategic corporate venture fund established in 2017
